

INNOVA CAPTAB LIMITED  
1281/1, Hilltop Industrial Estate, Near  
EPIP, Phase-I, Jharmajri, Baddi, Dist.  
Solan (H.P.)-173205 India.  
Phone: +91-1795-650820



**07<sup>th</sup> August, 2025**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Symbol: INNOVACAP**  
**BSE Scrip Code: 544067**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor  
Plot No. C/1, "G" Block  
Bandra-Kurla Complex  
Bandra (E), Mumbai – 400051  
**NSE Symbol: INNOVACAP**

Dear Sir/Madam,

**Subject: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30<sup>th</sup> June, 2025.

The Press Release is available on the website of the Company at [www.innovacaptab.com](http://www.innovacaptab.com)

This is for your information and record.

Thanking you,

Yours faithfully,  
For **Innova Captab Limited**

**Neeharika Shukla**  
**Company Secretary and Compliance Officer**  
**Membership No.: A42724**

**Encl.: As above**

**INNOVA CAPTAB LIMITED**  
**Press Release**  
**Performance Review of Q1 FY26**

**Innova Captab Limited reported strong results for Q1 FY26, with Revenue from Operations at ₹ 351.5 crore and EBITDA at ₹ 56.6 crore**

**Registered YoY Revenue growth of 19% and EBITDA growth of 28%**

**Mumbai 7<sup>th</sup> August 2025:** Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter ending June 30<sup>th</sup>, 2025.

**Key Highlights**

**Q1 FY26 vs Q1 FY25**

- Revenue from Operations recorded robust growth of **19%** year-on-year, reaching ₹ **351.5 crore** in Q1 FY26, driven by introduction of new products (including that from newly commissioned Jammu plant) and market expansion
- Consolidated EBITDA stood at ₹ **56.6 crore** vs ₹ **44.3 crore** in Q1 FY25 signifying solid YoY growth of **28%**
- EBITDA margins improved to **16.1%** vs **15.1%** in Q1 FY25, mainly supported by expanded gross margin
- PAT increased by **5%** YoY to ₹ **31.0 crore**, reflecting resilience in the face of increased depreciation and finance expenses
- PAT margin stood at **8.8%**

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said **“The first quarter has provided us with a strong and confident start to the financial year 2026. We delivered solid growth, reflected in both a healthy expansion of our topline and a notable improvement in operating profitability.**

**We continued to make steady progress on our strategic initiatives, in line with our plans. Our newly commissioned facility in Jammu gained momentum during the quarter, and we expect this traction to accelerate in the coming quarters and beyond.**

**In a pivotal move, we have reorganized our business areas into two focused verticals: CDMO and Branded Generics to synchronize with our strategic vision. Over the years, we’ve built robust partnerships with our CDMO clients across global markets, while simultaneously strengthening our direct presence in India and other key international geographies.**

**We remain committed to executing our strategy with discipline and agility. With a strong foundation in place, we are confident in our ability to drive sustainable growth and long-term value for all stakeholders.”**

#### **Financial Performance**

**(amount in ₹ crore except otherwise mentioned)**

##### **Q1 FY26 vs Q1 FY25**

<b>Particulars</b>	<b>Q1 FY26</b>	<b>Q1 FY25</b>	<b>YoY Growth</b>
Revenue from Operations	<b>351.5</b>	<b>294.3</b>	<b>19%</b>
EBITDA	<b>56.6</b>	<b>44.3</b>	<b>28%</b>
EBITDA Margin (%)	<b>16.1%</b>	<b>15.1%</b>	<b>100 bps</b>
Profit after Tax	<b>31.0</b>	<b>29.5</b>	<b>5%</b>

## About Innova Captab Limited

*Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 300 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA among others.*

*For more details, please visit [www.innovacaptab.com](http://www.innovacaptab.com)*

---

**For more information, please contact:**

**Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg**

**Email: [investors@innovacaptab.com](mailto:investors@innovacaptab.com) / [ayush.garg@innovacaptab.com](mailto:ayush.garg@innovacaptab.com)**

### **DISCLAIMER:**

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.